MX2022001712A - Conjugados y usos de los mismos. - Google Patents
Conjugados y usos de los mismos.Info
- Publication number
- MX2022001712A MX2022001712A MX2022001712A MX2022001712A MX2022001712A MX 2022001712 A MX2022001712 A MX 2022001712A MX 2022001712 A MX2022001712 A MX 2022001712A MX 2022001712 A MX2022001712 A MX 2022001712A MX 2022001712 A MX2022001712 A MX 2022001712A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- conjugate
- present
- therapeutic molecule
- peptide carrier
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
- A61K47/6455—Polycationic oligopeptides, polypeptides or polyamino acids, e.g. for complexing nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Genetics & Genomics (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Psychology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1911403.2A GB201911403D0 (en) | 2019-08-09 | 2019-08-09 | Conjugate and uses thereof |
| PCT/GB2020/051891 WO2021028666A1 (en) | 2019-08-09 | 2020-08-07 | Conjugate and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022001712A true MX2022001712A (es) | 2022-05-13 |
Family
ID=67990936
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022001712A MX2022001712A (es) | 2019-08-09 | 2020-08-07 | Conjugados y usos de los mismos. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20220275372A1 (https=) |
| EP (1) | EP4010030A1 (https=) |
| JP (1) | JP7678654B2 (https=) |
| KR (1) | KR20220079524A (https=) |
| CN (2) | CN114615998B (https=) |
| AU (1) | AU2020327659A1 (https=) |
| BR (1) | BR112022002309A2 (https=) |
| CA (1) | CA3149700A1 (https=) |
| GB (1) | GB201911403D0 (https=) |
| IL (1) | IL290424A (https=) |
| MX (1) | MX2022001712A (https=) |
| SA (1) | SA522431627B1 (https=) |
| WO (1) | WO2021028666A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200131231A1 (en) | 2017-02-17 | 2020-04-30 | Oxford University Innovation Limited | Cell penetrating peptides |
| GB201812980D0 (en) | 2018-08-09 | 2018-09-26 | Univ Oxford Innovation Ltd | Cell-penetrating peptides |
| GB201812972D0 (en) | 2018-08-09 | 2018-09-26 | Univ Oxford Innovation Ltd | Cell-penetrating peptides |
| US12465646B2 (en) | 2018-12-07 | 2025-11-11 | Oxford University Innovation Limited | Linkers |
| WO2022171972A1 (en) * | 2021-02-12 | 2022-08-18 | Oxford University Innovation Limited | Cell-penetrating peptide conjugates and methods of their use |
| EP4304657A4 (en) * | 2021-03-12 | 2026-04-01 | Pepgen Inc | METHODS OF TREATMENT OF TYPE 1 MYOTONIC DYSTROPHY USING PEPTIDE-OLIGONUCLEOTIDE CONJUGATES |
| KR20250116673A (ko) * | 2022-11-21 | 2025-08-01 | 펩젠 인크. | 세포-침투 펩티드, 그의 접합체 및 그의 사용 방법 |
| WO2025033255A1 (ja) * | 2023-08-07 | 2025-02-13 | 東亞合成株式会社 | ペプチドフラグメント及びその利用 |
| WO2025033256A1 (ja) * | 2023-08-07 | 2025-02-13 | 東亞合成株式会社 | ペプチドフラグメント及びその利用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2049664T1 (sl) * | 2006-08-11 | 2012-04-30 | Prosensa Technologies Bv | Enojna veriga oligonukleotidov, komplementarna repetitivnim elementom, za zdravljenje genetskih bolezni, povezanih z nestabilnostjo dnk ponovitev |
| WO2009005793A2 (en) * | 2007-06-29 | 2009-01-08 | Avi Biopharma, Inc. | Tissue specific peptide conjugates and methods |
| US20100016215A1 (en) * | 2007-06-29 | 2010-01-21 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
| WO2009147368A1 (en) * | 2008-06-04 | 2009-12-10 | Medical Research Council | Peptides |
| US20110269665A1 (en) * | 2009-06-26 | 2011-11-03 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
| CN103998458B (zh) * | 2011-08-30 | 2018-10-09 | 医学研究理事会 | 具有中央疏水域的细胞穿透肽 |
| EP2900821B1 (en) * | 2012-09-25 | 2020-04-01 | Genzyme Corporation | Peptide-linked morpholino antisense oligonucleotides for treatment of myotonic dystrophy |
| RU2708237C2 (ru) | 2014-08-22 | 2019-12-05 | Общество с ограниченной ответственностью "НооГен" | Модифицированные олигонуклеотиды и способ их получения |
-
2019
- 2019-08-09 GB GBGB1911403.2A patent/GB201911403D0/en not_active Ceased
-
2020
- 2020-08-07 AU AU2020327659A patent/AU2020327659A1/en active Pending
- 2020-08-07 JP JP2022507761A patent/JP7678654B2/ja active Active
- 2020-08-07 CN CN202080071067.8A patent/CN114615998B/zh active Active
- 2020-08-07 CA CA3149700A patent/CA3149700A1/en active Pending
- 2020-08-07 MX MX2022001712A patent/MX2022001712A/es unknown
- 2020-08-07 KR KR1020227007655A patent/KR20220079524A/ko active Pending
- 2020-08-07 EP EP20754817.3A patent/EP4010030A1/en active Pending
- 2020-08-07 CN CN202510582562.XA patent/CN120837670A/zh active Pending
- 2020-08-07 WO PCT/GB2020/051891 patent/WO2021028666A1/en not_active Ceased
- 2020-08-07 BR BR112022002309A patent/BR112022002309A2/pt unknown
- 2020-08-07 US US17/631,654 patent/US20220275372A1/en active Pending
-
2022
- 2022-02-07 IL IL290424A patent/IL290424A/en unknown
- 2022-02-08 SA SA522431627A patent/SA522431627B1/ar unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN114615998A (zh) | 2022-06-10 |
| US20220275372A1 (en) | 2022-09-01 |
| JP2022543320A (ja) | 2022-10-11 |
| JP7678654B2 (ja) | 2025-05-16 |
| KR20220079524A (ko) | 2022-06-13 |
| CA3149700A1 (en) | 2021-02-18 |
| AU2020327659A1 (en) | 2022-02-24 |
| EP4010030A1 (en) | 2022-06-15 |
| CN114615998B (zh) | 2025-05-23 |
| SA522431627B1 (ar) | 2024-05-19 |
| GB201911403D0 (en) | 2019-09-25 |
| BR112022002309A2 (pt) | 2022-04-26 |
| CN120837670A (zh) | 2025-10-28 |
| WO2021028666A1 (en) | 2021-02-18 |
| IL290424A (en) | 2022-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022001712A (es) | Conjugados y usos de los mismos. | |
| RU2486198C2 (ru) | Антиген, ассоциированный с ревматоидным артритом | |
| MX2026000051A (es) | Peptidos penetrantes celulares | |
| PH12022500032A1 (en) | Conjugates of a cell-binding molecule with camptothecin analogs | |
| MX2025014047A (es) | Composiciones para usarse en el tratamiento de atrofia muscular y distrofia miotonica | |
| TW200738877A (en) | Immunostimulatory oligoribonucleotides | |
| UA84728C2 (ru) | ПРОЦЕСС ОБРАЗОВАНИЯ ИММУНОГЕННОГО КОНЪЮГАТА, ИММУНОГЕННЫЙ КОНЪЮГАТ БЕЛКА Aβ С БЕЛКОМ-НОСИТЕЛЕМ И ИММУНОЛОГИЧЕСКАЯ КОМПОЗИЦИЯ, КОТОРАЯ ЕГО СОДЕРЖИТ | |
| NZ790263A (en) | Exon skipping compositions for treating muscular dystrophy | |
| CR20190481A (es) | Composiciones de anticuerpo optimizados para el tratamiento de trastornos oculares | |
| WO2019136180A3 (en) | Heteroduplex nucleic acid molecules and uses thereof | |
| EA201992081A1 (ru) | Конъюгирование цитотоксических лекарственных средств посредством бис-связывания | |
| MY146566A (en) | Immunogenic peptide carrier conjugates and methods of producing same | |
| EP3949969A3 (en) | Benzazepine compounds, conjugates, and uses thereof | |
| EP4678240A3 (en) | Bridge linkers for conjugation of cell-binding molecules | |
| TW200621801A (en) | Antibody molecules having specificity for human IL-17 | |
| WO2014057436A3 (en) | Anticancer conjugate | |
| MX2021005346A (es) | Constructos de suministro para transcitosis y metodos relacionados. | |
| MX2021001546A (es) | Péptidos penetrantes celulares. | |
| PH12020500417A1 (en) | Anti-efgr antibody drug conjugates (adc) and uses thereof | |
| PH12022553153A1 (en) | Binding molecules for the treatment of cancer | |
| EP4357334A3 (en) | Conjugated oligonucleotide compounds, methods of making and uses thereof | |
| MX337358B (es) | Conjugados de disorazoles y sus derivados con moleculas de union con celulas, nuevos derivados de disorazol, procesos de fabricacion y usos de los mismos. | |
| PH12021551419A1 (en) | New conjugated nucleic acid molecules and their uses | |
| RU2016134328A (ru) | Конъюгаты фактора свёртывания крови vii | |
| RU2015147913A (ru) | Антитело против рецептора эпидермального фактора роста |